Azathioprine metabolite measurements: Its use in current clinical practice

Pediatric Transplantation

Volumn 8, Issue 6, 2004, Pages 606-608

  Rumbo, Carolina ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

6 thioguanine; Adherence; Toxicity; Transplant

Indexed keywords

AZATHIOPRINE; DRUG METABOLITE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHYLMERCAPTOPURINE; PURINE DERIVATIVE; TIOGUANINE; UNCLASSIFIED DRUG;

AUTOIMMUNE HEPATITIS; BONE MARROW SUPPRESSION; CONFERENCE PAPER; DRUG METABOLISM; HUMAN; HYPERSPLENISM; LEUKEMIA; LIVER CIRRHOSIS; MYCOSIS; ORGAN TRANSPLANTATION; PORTAL HYPERTENSION; VIRUS INFECTION;

AZATHIOPRINE; GUANINE NUCLEOTIDES; HUMANS; MONITORING, PHYSIOLOGIC; THIONUCLEOTIDES;

EID: 11144243378     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2004.00239.x     Document Type: Conference Paper

References (27)

1. ERIDANI S, TAGLIORETTI D, TISO R. Clinical trial of azathioprine, a new antileukaemic compound. Panminerva Med 1965: 7: 275-281.
2. SCHWARTZ R. Immunosuppression - back to the future. World J Surg 2000: 24: 783-786.
3. SHERIFF MH, YAYHA T, LEE HA. Is azathioprine necessary in renal transplantation? Lancet 1978: 1: 118-120.
4. BERTH-JONES J, TAKWALE A, TAN E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002: 147: 324-330.
5. MURPHY LA, ATHERTON D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol 2002: 147: 308-315.
6. ANDRIES S, CASAMAYOU L, SEMPOUX C, et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. Transplantation 2001: 72: 267-272.
7. KERKAR N, HADZIC N, DAVIES E, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998: 351: 409-413.
8. PETZ W, SONZOGNI A, BERTANI A, et al. A cause of late graft dysfunction after pediatric liver transplantation: de novo autoimmune hepatitis. Transplant Proc 2002: 34: 1958-1959.
9. HERNANDEZ H, KOVARIK P, WHITINGTON PF, ALONSO E. Autoimmune hepatitis as a late complication of liver transplantation. J Pediatr Gastroenterol Nutr 2001: 32: 131-136.
10. NEUBERGER J. Transplantation for autoimmune hepatitis. Semin Liver Dis 22: 4: 379-385.
11. LANGLEY P, UNDERHILL J, TREDGER M, NORRIS S, MCFARLANE I. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 2002: 37: 441-447.
12. LOWRY PW, FRANKLIN C, WEAVER A, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001: 49: 665-670.
13. INNOCENTI F, DANESI R, FAVRE C, et al. Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia. Ther Drug Monit 2000: 22: 375-382.
14. CUFFARI C, THEORET Y, LATOUR S, SEIDMAN G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996: 39: 401-406.
15. DUBINSKY MC, LAMOTHE S, YANG HY, TARGAN SR, SINNETT D, THEORET Y. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000: 118: 705-713.
16. CUFFARI C, HUNT S, BAYLESS T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001: 48: 642-646.
17. CUFFARI C, SEIDMAN EG, LATOUR S, THEORET Y. Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's patients on maintenance 6-mercaptopurine therapy. Can J Physiol Pharmacol 1996: 74: 580-585.
18. BELAICHE J, DESAGER JP. HORSMANS Y, LOUIS E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 2001: 1: 71-76.
19. BLOOMFELD RS, ONKEN JE. Mercaptopurine metabolite results in clinical gastroenterology practice. Aliment Pharmacol Ther 2003: 17: 69-73.
20. DUBINSKY M, YANG H, HASSARD P, et al. 6MP metabolite profiles provides a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002: 122: 904-915.
21. MEDINA J, GARCIA-BUEY L, MORENO-OTERO R. Review article: immunopathogenetic and therapeutic aspects of autoimmune hepatitis. Aliment Pharmacol Ther 2003: 17: 1-16.
22. JOHNSON P, MCFARLANE I, WILLIAMS R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995: 333: 958-963.
23. HENEGHAN M, MCFARLANE I. Current novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002: 35: 7-13.
24. RUMBO C, EMERICK K, EMRE S, SHNEIDER B. Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients; a preliminary report. J Pediatr Gastroenterol Nutr 2002: 35: 391-398.
25. BUNZEL B, LAEDERACH-HOFMANN K. Solid organ transplantation: are there predictors for posttransplant noncompliance? A literature overview. Transplantation 2000: 70: 711-716.
26. LAEDERACH-HOFMANN K, BUNZEL B. Noncompliance in organ transplant recipients: a literature review. Gen Hosp Psychiatry 2000: 22: 412-424.
27. LAU R, MATSUI D, GREENBERG M, KOREN G. Electronic measurement of compliance in pediatric patients with acute lymphoblastic leukemia. Med Pediatr Oncol 1998: 30: 85-90.